论文部分内容阅读
目的:观察罗格列酮(RSG)治疗2型糖尿病(T2DM)对患者生存质量(QOL)和男性性功能的影响。方法:男性T2DM患者92例,按临床资料相似匹配,随机分为2组,RSG组给予RSG,格列齐特(GLC)给予GLC,共26周,治疗前后测FPG、2hPG、HbA1c,并以QOL量表评估患者QOL。以O′LeaIY1995《男性性功能问卷》评估性功能。结果:QOL评分RSG组从(182.7±46.7)VS(132.0±32.6),优于GLC组,性功能评分RSG组从(25.3±11.6)升至(36.7±12.4),亦显著优于GLC组(P<0.01)。结论:RSG治疗能显著提高T2DM患者生活质量和男性性功能。
Objective: To observe the effect of rosiglitazone (RSG) on type 2 diabetes mellitus (T2DM) on quality of life (QOL) and male sexual function. Methods: A total of 92 male patients with T2DM were randomly divided into two groups according to the clinical data. The RSG group was given RSG and the GLC was given GLC for 26 weeks. FPG, 2hPG and HbA1c were measured before and after treatment QOL scale to assess patient QOL. Sexual function was assessed using O’Leal’s 1995 Men’s Sexual Function Questionnaire. Results: The score of QOL in RSG group was significantly higher than that in GLC group (182.7 ± 46.7) VS (132.0 ± 32.6) vs GLC group (25.3 ± 11.6) and (36.7 ± 12.4) in RSG group P <0.01). Conclusion: RSG treatment can significantly improve the quality of life and male sexual function in patients with T2DM.